CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

PURPOSE: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. METHODS: Participants with chronic pain (94% on...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Genet Med
Prif Awduron: Smith, D. Max, Weitzel, Kristin W., Elsey, Amanda R., Langaee, Taimour, Gong, Yan, Wake, Dyson T., Duong, Benjamin Q., Hagen, Melanie, Harle, Christopher A., Mercado, Elvira, Nagoshi, Ying, Newsom, Kimberly, Wright, Ashleigh, Rosenberg, Eric I., Starostik, Petr, Clare-Salzler, Michael J., Schmidt, Siegfried O., Fillingim, Roger B., Johnson, Julie A., Cavallari, Larisa H.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2019
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6650382/
https://ncbi.nlm.nih.gov/pubmed/30670877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41436-018-0431-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg